Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

Launched by INSIGHTEC · Nov 18, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to treat a type of brain tumor called DIPG (diffuse intrinsic pontine glioma) in children and young adults. The study is testing a combination of a special ultrasound technique, called Exablate, which helps open the blood-brain barrier, and a chemotherapy drug called Doxorubicin. The goal is to see if this approach is safe and effective for patients aged 5 to 21 who have recently completed radiation therapy for their tumor.

To participate, patients need to be within the age range and have been diagnosed with DIPG. They should have finished radiation therapy between 4 to 12 weeks ago and must be in stable health, meaning they have no significant complications from their treatment. Participants will attend regular study visits, where they will receive the new treatment and be closely monitored for any side effects. It’s important to note that certain medical conditions and previous treatments might prevent some patients from joining the study, so a thorough review of their health history is required. Overall, this trial aims to find better ways to help young patients facing this challenging diagnosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 5 and 21 years, inclusive. Subjects younger than 5 years old may be eligible after discussion with the Sponsor Medical Monitor/designee (i.e. DSMB).
• • Patient diagnosed with DIPG
• • At least 4-week and not greater than 12 weeks from completion of radiation therapy
• • Post-radiation imaging does not show evidence of necrosis/ hemorrhage or other features that contraindicate MRgFUS
• • If brain surgery occurred, at least 14 days passed since last brain surgery and the patient is fully recovered and neurologically stable
• • If on steroids, stable or decreasing dose for at least 7 days prior to study entry
• • Stable or improving neurologic status for 7 days prior to study entry
• • Able and willing to give consent and/or assent or have a legal guardian who is able and willing to do so
• • Able to attend all study visits and with life expectancy of at least 6 months
• Exclusion Criteria:
• • Tumor not visible on any pre-therapy or post-radiation imaging
• • Previous participation in other chemotherapy, molecularly targeted therapy, or immunotherapy treatment-related phase 1 or 2 trials
• • Symptoms and signs of increased intracranial pressure
• • Subject with metastatic disease
• • Subject with ventricular peritoneal shunt
• • Subject receiving bevacizumab (Avastin) therapy or increasing doses of steroids
• • Anti-coagulant therapy, or medications known to increase risk of hemorrhage, (e.g., ASA, non-steroidal anti-inflammatory drugs \[NSAIDs\], statins) within washout period prior to treatment
• • History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor hemorrhage.
• • Hypertension per age
• • Cerebral or systemic vasculopathy, including intracranial thrombosis, vascular malformation, cerebral aneurysm, or vasculitis
• • Immunosuppression (corticosteroids to prevent/treat brain edema are permitted).
• • Patients with positive HIV status
• • Active seizure disorder or epilepsy (seizures despite medical treatment) for a minimum of 4 weeks prior to first cycle/Exablate BBBD procedure captured by history
• • Known sensitivity to gadolinium-based contrast agents
• • Known sensitivity to DEFINITY® ultrasound contrast agent or known hypersensitivity to perflutren microsphere or its components, e.g., polyethylene glycol
• • Contraindication to Doxorubicin
• • Previous treatment with complete cumulative doses of Doxorubicin, daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones
• • Severely impaired renal function with estimated glomerular filtration rate \<2 standard deviations for age
• • Patients that may require trastuzumab during the study
• • Patients that may require inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp during the study